المؤلفون: Benitez‐Hidalgo, Olga, Suito Alcántara, Milagros, Martinez Garcia, Maria Fernanda, Campoy, Desiree, Olivera, Pavel, Gironella Mesa, Mercedes, Juarez‐Gimenez, Juan Carlos

المصدر: Clinical Case Reports ; volume 12, issue 2 ; ISSN 2050-0904 2050-0904

الوصف: Key Clinical Message The increased life expectancy in patients with hemophilia (PwH) over the last years has raised the incidence of comorbidities, including thromboembolic events. Thromboembolic events are rare in PwH and most of them occur in the presence of exogenous risk factors. There is still scarce scientific evidence on the optimal antithrombotic treatment and management approach in this population. Abstract In the hemophilic population thromboembolic events are rare. Most of them are often multifactorial and occur in the presence of both exogenous (orthopedic surgery, intensive replacement therapy, use of central venous catheters…) and endogenous (cardiovascular diseases) risk factors. We describe the case of a 43‐year‐old patient with severe hemophilia B (sHB) receiving prophylaxis with eftrenonacog alfa (rFIXFc) and antithrombotic treatment due to portal vein thrombosis. The patient was treated with extended half‐ life factor IX (EHL‐FIX) prophylaxis maintaining higher trough levels to avoid new bleeding episodes associated to the underlying disease and the use of antithrombotic therapy with low molecular weight heparin. EHL‐FIX concentrates allow prolonged intervals between intravenous infusions and higher hemostatic protection thanks to increased factor trough levels. This current case report provides clinical evidence in antithrombotic management in a patient with severe hemophilia B.

الإتاحة: https://doi.org/10.1002/ccr3.8121Test

المؤلفون: de la Rubia, Javier, González, Bernardo, Cruz-Jentoft, Alfonso J., Iglesias, Lorena, Pérez Persona, Ernesto, Gironella Mesa, Mercedes, Jarque, Isidro

المساهمون: Institut Català de la Salut, de la Rubia J, Jarque I Hematology Department, H.U. i Politècnic La Fe. Valencia, Spain. School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC CB16/12/00284, Instituto de Salud Carlos III. Madrid, Spain. González B Hematology Department, H.U. de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain. Cruz-Jentoft AJ Geriatric Unit, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain. Iglesias L Hematology Department, C.H.U. A Coruña. A Coruña, Spain. Persona EP Hematology Department H. U, Vitoria-Gasteiz, Álava, Spain. Gironella M Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Persones grans, Sang - Malalties - Diagnòstic, Medicaments - Toxicologia, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Geriatric Assessment, PUBLIC HEALTH::Environmental Health::Science::Toxicology::Toxicity, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::evaluación geriátrica, SALUD PÚBLICA::salud ambiental::ciencia::toxicología::toxicidad

الوصف: Chemotherapy; Geriatric assessment; Toxicity ; Quimioterapia; Evaluación geriátrica; Toxicidad ; Quimioteràpia; Avaluació geriàtrica; Toxicitat ; Introduction The GAH (Geriatric Assessment in Hematology) scale is a psychometrically valid tool aimed at identifying older patients with hematological malignancies at higher risk of treatment-related toxicity. Our objective in this study was to determine the weights for each dimension of the GAH scale and the cut-off point to reliably predict treatment tolerability in this population, estimated by a weighted receiver operating characteristic (ROC) analysis and quantified by the area under the curve (AUC). Material and Methods The RETROGAH was a retrospective cohort study including 126 patients who had previously participated in the GAH study. Patients were ≥ 65 years old with newly diagnosed myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), multiple myeloma (MM), or chronic lymphoid leukemia (CLL) and treated with standard front-line therapy within three months after having completed the GAH scale. Results The optimal cut-off value of the GAH total score to discriminate patients at higher risk of treatment toxicity was 42, with 68.5% sensitivity and 55.8% specificity. Using this value, 66.1% of patients evaluated were found to develop some type of toxicity. The AUC was 0.6259 (95% CI: 0.512–0.739; p = 0.035). Discussion The GAH scale not only would enable clinicians to individualize therapy based on individual risk of toxicity but also discriminate patients that will benefit most from intensive treatments from those requiring an adapted approach. While futures studies in clinical practice may improve the model and overcome its limitations, the GAH scale should not be used alone when making treatment decisions. ; This study was supported by Celgene España S.L.

وصف الملف: application/pdf

العلاقة: Journal of Geriatric Oncology;14(1); https://doi.org/10.1016/j.jgo.2022.10.016Test; de la Rubia J, González B, Cruz-Jentoft AJ, Iglesias L, Jarque I, Persona EP, et al. Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study. J Geriatr Oncol. 2023 Jan;14(1):101401.; https://hdl.handle.net/11351/9326Test; 000946209600001

الإتاحة: https://doi.org/10.1016/j.jgo.2022.10.016Test
https://hdl.handle.net/11351/9326Test

المؤلفون: Mateos, Maria-Victoria, Engelhardt, Monika, Leleu, Xavier, Gironella Mesa, Mercedes, Auner, Holger W., Cavo, Michele, Dimopoulos, Meletios A., Bianco, Martina, Marino Merlo, Giovanni, la Porte, Charles, Moreau, Philippe

المصدر: HemaSphere ; volume 7, issue S3, page e7454106 ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000970572.74541.06Test

المؤلفون: Mateos, Maria-Victoria, Engelhardt, Monika, Leleu, Xavier, Gironella Mesa, Mercedes, Auner, Holger W., Cavo, Michele, Dimopoulos, Meletios A., Bianco, Martina, Marino Merlo, Giovanni, la Porte, Charles, Moreau, Philippe

المصدر: HemaSphere ; volume 7, issue S3, page e1470834 ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000970448.14708.34Test

المؤلفون: Jimenez Balarezo, Moraima, Roldan Galvan, Elisa, Fernandez Naval, Candela, Medina-Gil, Daniel, Peralta Garzon, Soraya, Pujadas, Gemma, Hernández Buñuel, Cristina, Pagès Geli, Carlota, Gironella Mesa, Mercedes, Orti Pascual, Guillem, Barba Suñol, Pere, Pumarola Suñé, Tomàs, Cabirta Touzon, Alba, Catalá, Eva, Valentin, Mercedes, Orfao, Alberto, González, Marcos, Ruiz Camps, Isabel, Valcarcel Ferreiras, David, Bosch Albareda, Francesc, Hernández González, Manuel, Crespo Maull, Marta, Esperalba Esquerra, Juliana, Villacampa Javierre, Guillermo, Marin Niebla, Ana, Martínez Gallo, Mónica, Fox, Maria Laura, Abrisqueta, Pau, Campins Martí, Magda

المساهمون: Institut Català de la Salut, Jiménez M, Roldán E, Gironella M, Fox L, Orti G, Barba P, Valcárcel D, Bosch F, Abrisqueta P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Fernández-Naval C, Pumarola T, Esperalba J Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Villacampa G Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Martinez-Gallo M, Hernández M Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Crespo M Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Cabirta A, Catalá E, Valentín M, Marín-Niebla A Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Orfao A Department of Medicine and Cytometry General ServiceNucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain. González M Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC–CB16/12/00233 and Center for Cancer Research–IBMCC (USAL-CSIC), Salamanca, Spain. Campins M Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ruiz-Camps I Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: COVID-19 (Malaltia) - Vacunació, Immunoglobulines, Sang - Malalties, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, PHENOMENA AND PROCESSES::Immune System Phenomena::Antibody Formation::Immunogenicity, Vaccine, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus, FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::formación de anticuerpos::inmunogenicidad vacunal

الوصف: Immunobiology; Immunotherapy ; Inmunobiología; Inmunoterapia ; Immunobiologia; Immunoteràpia ; Recent studies have shown a suboptimal humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients diagnosed with hematologic malignancies; however, data about cellular immunogenicity are scarce. The aim of this study was to evaluate both the humoral and cellular immunogenicity 1 month after the second dose of the mRNA-1273 vaccine. Antibody titers were measured by using the Elecsys and LIAISON anti–SARS-CoV-2 S assays, and T-cell response was assessed by using interferon-γ release immunoassay technology. Overall, 76.3% (184 of 241) of patients developed humoral immunity, and the cellular response rate was 79% (184 of 233). Hypogammaglobulinemia, lymphopenia, active hematologic treatment, and anti-CD20 therapy during the previous 6 months were associated with an inferior humoral response. Conversely, age >65 years, active disease, lymphopenia, and immunosuppressive treatment of graft-versus-host disease (GVHD) were associated with an impaired cellular response. A significant dissociation between the humoral and cellular responses was observed in patients treated with anti-CD20 therapy (the humoral response was 17.5%, whereas the cellular response was 71.1%). In these patients, B-cell aplasia was confirmed while T-cell counts were preserved. In contrast, humoral response was observed in 77.3% of patients undergoing immunosuppressive treatment of GVHD, whereas only 52.4% had a cellular response. The cellular and humoral responses to the SARS-CoV-2 mRNA-1273 vaccine in patients with hematologic malignancies are highly influenced by the presence of treatments such as anti-CD20 therapy and immunosuppressive agents. This observation has implications for the further management of these patients.

وصف الملف: application/pdf

العلاقة: Blood Advances;6(3); https://doi.org/10.1182/bloodadvances.2021006101Test; Jimenez M, Roldan E, Fernandez-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774–84.; https://hdl.handle.net/11351/8614Test; 000754263400007

الإتاحة: https://doi.org/10.1182/bloodadvances.2021006101Test
https://hdl.handle.net/11351/8614Test

المؤلفون: Benitez Hidalgo, Olga, Bescós Cabestre, Agustí, Juarez Giménez, Juan Carlos, Gironella Mesa, Mercedes, Bosch Albareda, Francesc, Martinez Garcia, Maria Fernanda

المساهمون: Institut Català de la Salut, Benitez Hidalgo O, Martinez Garcia MF, Gironella Mesa M, Bosch Albareda F Experimental Hematology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Bescos Cabestre A Servei de Neurocirurgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Juarez Gimenez JC Servei de Farmàcia Hospitalària, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Sistema nerviós - Cirurgia, Hemofília - Tractament, Proteïnes recombinants - Ús terapèutic, DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders::Blood Coagulation Disorders, Inherited::Hemophilia B, Other subheadings::Other subheadings::Other subheadings::/drug therapy, DISCIPLINES AND OCCUPATIONS::Health Occupations::Medicine::Specialties, Surgical::Neurosurgery, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Recombinant Proteins::Recombinant Fusion Proteins, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos de la coagulación sanguínea::trastornos de la coagulación sanguínea hereditarios::hemofilia B, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, DISCIPLINAS Y OCUPACIONES::profesiones sanitarias::medicina::especialidades quirúrgicas::neurocirugía, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas recombinantes::proteínas de fusión recombinantes

الوصف: Anesthesia; Haemophilia B; Neurosurgery ; Anestesia; Hemofilia B; Neurocirugía ; Anestèsia; Hemofília B; Neurocirurgia ; Extended half-life FIX (EHL-FIX) concentrates have been developed with the purpose of reducing the frequency of infusions in patients with severe or moderate hemophilia B. We describe the case of a 63-year-old patient with severe hemophilia B (sHB) treated with FIX-Fc fusion protein (rFIXFc) who underwent neurosurgery.

وصف الملف: application/pdf

العلاقة: Clinical Case Reports;10(5); https://doi.org/10.1002/ccr3.5848Test; Benitez Hidalgo O, Martinez Garcia MF, Bescos Cabestre A, Juarez Gimenez JC, Gironella Mesa M, Bosch Albareda F. Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management. Clin Case Reports. 2022 May;10(5):e05848.; https://hdl.handle.net/11351/8056Test; 000798984900001

الإتاحة: https://doi.org/10.1002/ccr3.5848Test
https://hdl.handle.net/11351/8056Test

المؤلفون: Puig, Noemi, Hernández, Miguel T., González, Esther, de Arriba, Felipe, Gironella Mesa, Mercedes, Rosiñol, Laura, Oriol, Albert

المساهمون: Institut Català de la Salut, Puig N Hematology Department, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. Hernández MT Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. Rosiñol L Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain. González E Hospital Universitario de Cabueñes, Gijón, Spain. de Arriba F Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain. Oriol A Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain. Gironella M Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Mieloma múltiple - Tractament, Teràpia cel·lular, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Transplantation::Transplantation, Autologous, AND EQUIPMENT::Therapeutics::Drug Therapy::Drug Therapy, Combination, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::trasplante::trasplante autólogo, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::farmacoterapia combinada

الوصف: Mieloma; Assajos controlats aleatoris ; Mieloma; Ensayos controlados aleatorios ; Myeloma; Randomized controlled trials ; Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 patients with MM ineligible for ASCT received Rd with or without clarithromycin until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). With a median follow-up of 19 months (range, 0–54), no significant differences in the median PFS were observed between the two arms (C-Rd 23 months, Rd 29 months; HR 0.783, p = 0.14), despite a higher rate of complete response (CR) or better in the C-Rd group (22.6% vs 14.4%, p = 0.048). The most common G3–4 adverse events were neutropenia [12% vs 19%] and infections [30% vs 25%], similar between the two arms; however, the percentage of toxic deaths was higher in the C-Rd group (36/50 [72%] vs 22/40 [55%], p = 0.09). The addition of clarithromycin to Rd in untreated transplant ineligible MM patients does not improve PFS despite increasing the ≥CR rate due to the higher number of toxic deaths in the C-Rd arm. Side effects related to overexposure to steroids due to its delayed clearance induced by clarithromycin in this elderly population could explain these results. The trial was registered in clinicaltrials.gov with the name GEM-CLARIDEX: Ld vs BiRd and with the following identifier NCT02575144. The full trial protocol can be accessed from ClinicalTrials.gov. This study received financial support from BMS/Celgene.

وصف الملف: application/pdf

العلاقة: Blood Cancer Journal;11; https://doi.org/10.1038/s41408-021-00490-8Test; Puig N, Hernández MT, Rosiñol L, González E, de Arriba F, Oriol A, et al. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer J. 2021 May 21;11:101.; https://hdl.handle.net/11351/6807Test; 000657750600003

الإتاحة: https://doi.org/10.1038/s41408-021-00490-8Test
https://hdl.handle.net/11351/6807Test

المؤلفون: Dimopoulos, Meletios, Sanz, Ramon Garcia, Lee, Hui-Peng, Trneny, Marek, Varettoni, Marzia, Opat, Stephen, D'Sa, Shirley, Owen, Roger G., Cull, Gavin, Mulligan, Stephen, Czyz, Jaroslaw, Castillo, Jorge J., Motta, Marina, Siddiqi, Tanya, Gironella Mesa, Mercedes, Granell Gorrochategui, Miquel, Talaulikar, Dipti, Zinzani, Pier Luigi, Askari, Elham, Grosicki, Sebastian, Oriol, Albert, Rule, Simon, Kloczko, Janusz, Tedeschi, Alessandra, Buske, Christian, Leblond, Veronique, Trotman, Judith, Chan, Wai Y., Michel, Jan, Schneider, Jingjing, Tan, Ziwen, Cohen, Aileen, Huang, Jane, Tam, Constantine S.

مصطلحات موضوعية: Humans, Myeloid Differentiation Factor 88/genetics, Waldenstrom Macroglobulinemia/drug therapy/genetics, Piperidines, Pyrazoles/adverse effects, Pyrimidines/adverse effects

الوصف: Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the MYD88 gene (MYD88WT) have demonstrated relatively poor outcomes to ibrutinib monotherapy, with no major responses reported in a phase 2 pivotal study. Zanubrutinib is a novel, selective Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target activity. The ASPEN study consisted of a randomized comparison of zanubrutinib and ibrutinib efficacy and safety in patients with WM who have the MYD88 mutation, as well as a separate cohort of patients without MYD88 mutation (MYD88WT) or with unknown mutational status who received zanubrutinib. Results from the latter single-arm cohort are reported herein. Efficacy endpoints included overall, major and complete (CR) or very good partial response (VGPR) rates, progression-free survival (PFS), duration of response (DOR), and overall survival (OS). Twenty-eight patients (23 relapsed/refractory; 5 treatment-naive) were enrolled, including 26 with centrally confirmed MYD88WT disease and 2 with unknown MYD88 mutational status. At a median follow-up of 17.9 months, 7 of 26 MYD88WT patients (27%) had achieved a VGPR and 50% a major response (partial response or better); there were no CRs. At 18 months, the estimated PFS and OS rates were 68% and 88%, respectively, while the median DOR had not been reached. Two patients discontinued zanubrutinib due to adverse events. Treatment-emergent hypertension, atrial fibrillation, and major hemorrhages were reported in 3, 1 and 2 patients (including 1 concurrent with enoxaparin therapy), respectively. Results of this substudy demonstrate that zanubrutinib monotherapy can induce high quality responses in patients with MYD88WT WM. This trial is registered on www.clinicaltrials.gov as NCT #03053440. ; The article is available via Open Access. Click on the 'Additional link' above to access the full-text. ; Not permitted

العلاقة: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33284944Test/; Dimopoulos, M. et al. (2020) 'Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.', Blood advances, 4(23), pp. 6009-6018. doi:10.1182/bloodadvances.2020003010.; https://rde.dspace-express.com/handle/11287/621842Test; Blood advances; PMC7724905

الإتاحة: https://doi.org/10.1182/bloodadvances.2020003010Test
https://rde.dspace-express.com/handle/11287/621842Test

المؤلفون: Medina, Alejandro, Jimenez, Cristina, Sarasquete, Maria Eugenia, González, Marcos, Chillón, M. Carmen, Balanzategui, Ana, Gironella Mesa, Mercedes

المساهمون: Institut Català de la Salut, Medina A, Jiménez C, Sarasquete ME, González M, Chillón MC, Balanzategui A Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. Gironella M Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Mieloma múltiple, Regulació genètica, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma, PHENOMENA AND PROCESSES::Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation, Neoplastic, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple, FENÓMENOS Y PROCESOS::fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica

الوصف: Investigació genètica; Mieloma ; Investigación genética; Mieloma ; Genetics research; Myeloma ; Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features in the outcome has not been extensively explored. Here we present the characterization of complete heavy-chain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by next-generation sequencing. Compared to the normal B-cell repertoire, gene selection was biased in myeloma, with significant overrepresentation of IGHV3, IGHD2 and IGHD3, as well as IGHJ4 gene groups. Hypermutation was high in our patients (median: 8.8%). Interestingly, regarding patients who are not candidates for transplantation, a high hypermutation rate (≥7%) and the use of IGHD2 and IGHD3 groups were associated with improved prognostic features and longer survival rates in the univariate analyses. Multivariate analysis revealed prolonged progression-free survival rates for patients using IGHD2/IGHD3 groups (HR: 0.552, 95% CI: 0.361−0.845, p = 0.006), as well as prolonged overall survival rates for patients with hypermutation ≥7% (HR: 0.291, 95% CI: 0.137−0.618, p = 0.001). Our results provide new insights into the molecular characterization of multiple myeloma, highlighting the need to evaluate some of these clonal rearrangement characteristics as new potential prognostic markers. ; This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness PI15/01956, CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010)”. M.G.-A., I.P.-C., and C.J. are supported by the Fundación Española de Hematología y Hemoterapia (FEHH, co-funded by Fundación Cris in the latter case), A.M. by the European Social Fund and the Spanish Education Council through the University of Salamanca, and M.E.S. by ...

وصف الملف: application/pdf

العلاقة: Blood Cancer Journal;10; https://doi.org/10.1038/s41408-020-0283-8Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F01956; info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F12%2F00233; info:eu-repo/grantAgreement/ES/PE2013-2016/CPII18%2F00028; Medina A, Jiménez C, Sarasquete ME, González M, Chillón MC, Balanzategui A, et al. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. Blood Cancer J. 2020 Feb 6;10:14.; https://hdl.handle.net/11351/6280Test; 000512747500001

الإتاحة: https://doi.org/10.1038/s41408-020-0283-8Test
https://hdl.handle.net/11351/6280Test

المؤلفون: Martinez-Lopez, Joaquin, Mateos, María-Victoria, Encinas, Cristina, Sureda, Anna, Hernández-Rivas, José Ángel, Lopez de la Guía, Ana, Gironella Mesa, Mercedes

المساهمون: Institut Català de la Salut, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Mieloma múltiple, COVID-19 (Malaltia), Mortalitat, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma, DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::mortalidad

الوصف: Malalties infeccioses; Mieloma; Pronòstic ; Enfermedades infecciosas; Mieloma; Pronóstico ; Infectious diseases; Myeloma; Prognosis ; There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.

وصف الملف: application/pdf

العلاقة: Blood Cancer Journal;10; https://doi.org/10.1038/s41408-020-00372-5Test; Martínez-López J, Mateos MV, Encinas C, Sureda A, Hernández-Rivas JÁ, Lopez de la Guía A, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020 Oct 19;10:103.; https://hdl.handle.net/11351/6282Test; 000586453500001

الإتاحة: https://doi.org/10.1038/s41408-020-00372-5Test
https://hdl.handle.net/11351/6282Test